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Purpose: IBTR! 2.0 nomogram is web-based nomogram that predicts ipsilateral breast tumor recurrence (IBTR). We aimed to 
validate the IBTR! 2.0 using an external data set.
Materials and Methods: The cohort consisted of 2,206 patients, who received breast conserving surgery and radiation therapy 
from 1992 to 2012 at our institution, where wide surgical excision is been routinely performed. Discrimination and calibration were 
used for assessing model performance. Patients with predicted 10-year IBTR risk based on an IBTR! 2.0 nomogram score of <3%, 
3%–5%, 5%–10%, and >10% were assigned to groups 1, 2, 3, and 4, respectively. We also plotted calibration values to observe the 
actual IBTR rate against the nomogram-derived 10-year IBTR probabilities.
Results: The median follow-up period was 73 months (range, 6 to 277 months). The area under the receiver operating 
characteristic curve was 0.607, showing poor accordance between the estimated and observed recurrence rate. Calibration plot 
confirmed that the IBTR! 2.0 nomogram predicted the 10-year IBTR risk higher than the observed IBTR rates in all groups. High 
discrepancies between nomogram IBTR predictions and observed IBTR rates were observed in overall risk groups. Compared with the 
original development dataset, our patients had fewer high grade tumors, less margin positivity, and less lymphovascular invasion, 
and more use of modern systemic therapies. 
Conclusions: IBTR! 2.0 nomogram seems to have the moderate discriminative ability with a tendency to over-estimating risk rate. 
Continued efforts are needed to ensure external applicability of published nomograms by validating the program using an external 
patient population.  
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Introduction
As the incidence of breast cancer has increased constantly, the 
proportion of breast-conserving surgery (BCS) has increased 
rapidly since 2002 in Korea [1,2]. Following thyroid cancer, 
breast cancer is the second most common female cancer in 
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Korea. Radiotherapy (RT) has been recommended as a standard 
treatment for several decades and proved to reduce 10-
year risk of any first recurrence and 15-year breast cancer 
death risk [3,4]. Considering the importance of quality of life 
and cosmetics, BCS and RT is preferred over a mastectomy 
approach.
Nomograms are a predictive tool that can provide an overall 
expectation of a specific outcome. Nomograms are widely 
used to assess numerous malignancies and to estimate cancer 
prognosis; the IBTR! is a popular nomogram that can predict 
ipsilateral breast tumor recurrence (IBTR) after BCS. The IBTR! 
1.0 nomogram is the initial version of the nomogram that uses 
seven prognostic factors: age, tumor size, tumor grade, margin 
status, lymphovascular invasion (LVI), chemotherapy usage and 
hormone therapy usage [5]. The IBTR! 2.0 was optimized with 
data on 7,811 patients found in the British Columbia Cancer 
Agency (BCCA) breast cancer database between 1989 and 
1999 [6]. Despite its clinical utility, there is a potential risk that 
nomograms overestimate and underestimate the actual rate. 
Before implementing the nomogram as useful clinical tool at 
any institution, objective validation with a specific dataset is 
critically important.
In our institution, wide surgical excision has been 
routinely conducted. Breast surgeons resect enough margins 
encompassing the entire cavity of the tumor bed, providing 
less local recurrence than currently recommended boundaries 
for inked-margins [7]. This study aimed to evaluate the efficacy 
of the IBTR! 2.0 nomogram at our institution.
Materials and Methods
1. Patients
From January 1991 to December 2012, a total of 2,206 
patients who received BCS with RT at Yonsei Cancer Center 
were reviewed retrospectively. Patients with in situ tumors, 
with distant metastasis at the time of diagnosis, or patients 
who received BCS without RT were excluded. Approval for this 
study was granted by the Institutional Review Board of Yonsei 
University Hospital (No. 2017-1146-001).
2. Treatment 
BCS was performed by wide excision of the primary tumor 
with a safety margin over 1 cm. The resection margin was 
shaved all around to eliminate any remnant breast tissue. The 
resection margin was marked with blue-colored ink far from 
the originally located tumor site and evaluated by the frozen 
section analysis. Microscopically involved margins were re-
excised to achieve the negative margin. Along with breast 
surgery, sentinel lymph node biopsy or standard axillary lymph 
node dissections were completed. From early 2000, sentinel 
lymph node biopsy using radioisotopes have been performed. 
Patients with positive sentinel lymph nodes underwent axillary 
node dissection. 
Patients received whole breast RT using a tangential 
technique after BCS. Target delineation was performed 
using the European Society for Radiotherapy and Oncology 
guidelines [8,9]. A total of 50.4 Gy with 1.8–2 Gy per fraction 
was applied for the whole breast with or without regional 
nodal area. Four to 6 MV X-ray linear accelerators were used 
for whole breast irradiation. Sequentially, 10 Gy with 2 Gy per 
fraction for a boost to the tumor bed were performed with 
an electron beam. For patients with positive axillary lymph 
node or medially located tumors, regional node irradiation was 
performed including supraclavicular lymph nodes, internal 
mammary lymph nodes and axillary lymph nodes [10]. 
Selective estrogen receptor modulators or aromatase 
inhibitors were recommended in patients with hormone 
receptor positive tumors. Trastuzumab has been recommended 
for use in human epidermal growth factor receptor 2 positive 
tumors since 2005 at our institution. The chemotherapy 
regimen was determined according to standard treatment 
guidelines. Patients with a tumor size larger than 0.5 cm 
or positive regional lymph nodes received Adriamycin 
and cyclophosphamide every 21 days for 4 cycles with an 
additional 12 cycles of paclitaxel every week. Omitting the 
paclitaxel was considered in women with negative regional 
lymph nodes. 
3. Follow-up  
Physical examination, radiologic imaging studies, laboratory 
tests were performed for follow-up every 6 months for 5 
years, and then every year up to 10 years. Ultrasound imaging 
was performed every 6 months, and a mammography was 
conducted every year to evaluate locoregional recurrence up 
to 5 years. Magnetic resonance imaging was performed at 2 
and 5 years after BCS.
4. Study endpoint and statistical analysis
The primary endpoint of this study was to validate the IBTR! 
2.0 nomogram. In this study, the IBTR was defined as tumor 
recurrence in the ipsilateral breast. The secondary endpoint 
was to determine the patterns of recurrence in patients 
receiving BCS and RT.
All estimated 10-year IBTR in this study were calculated 
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using the IBTR! 2.0 website application. To evaluate model 
performance, we assessed discrimination and calibration. 
Discrimination refers the ability to discriminate classes of 
outcomes. To evaluate discriminative ability of this model, 
receiver operating characteristic (ROC) and area under the 
curve were utilized.
Calibration helps to demonstrate how far the estimation 
value is from the actual outcomes. In this study, calibration 
plots were used to assess the calibration by the observed 
IBTR rate against the nomogram-derived IBTR probabilities; 
observed and predicted outcomes form a 45° line in a perfectly 
calibrated nomogram. Also, we showed the Kaplan-Meier IBTR 
curves of 4 risk groups according to their estimated 10-yr IBTR 
rate by nomogram: group 1, <3%, group 2, 3%–5%; group 3, 
5%–10%; group 4, >10%. 
Overall survival (OS) and disease-free survival (DFS) rates 
were also calculated using Kaplan-Meier methods. The OS was 
defined as the time interval between the date of breast surgery 
and the date of death. The DFS was defined as the time from 
the surgery to the first locoregional recurrence, systemic 
recurrence or death. Univariate and multivariate analysis using 
the Cox proportional hazard model was performed to evaluate 
the factors affecting the OS, DFS, and IBTR independently. A 
p-value less than 0.05 were judged as statistically significant. 
B
Table 1. Comparison of patient characteristics with BCCA cohort and University Hospital Leuven cohort (development set of IBTR! 2.0 
nomogram)
YCC 
(n = 2,206)
BCCA [6] 
(n = 7,811)
University Hospital Leuven cohort [11]
(n = 1,898)
Age (yr)
Tumor size (cm)
   ≤1
   1.1–2
   >2
Nodal statusa)
   Negative
   Positive
Gradea)
   1
   2
   3
Resection margina)
   Negative
   Close (≤ 2 mm)
   Positive 
Lymphovascular invasiona)
   No
   Yes
Chemotherapy
   No
   Yes
Hormonal therapy
   No
   Yes
Tumor laterality
   Right
   Left
Tumor locationa)
   Outer and central
   Inner
 49 (20–82)
 591 (26.80)
 1,086 (49.20)
 529 (24.00)
 1,753 (79.80)
 445 (20.20)
 564 (27.90)
 936 (46.30)
 520 (25.70)
 2,135 (96.90)
 12 (0.50)
 56 (2.50)
 2,082 (94.40)
 123 (5.60)
 790 (35.80)
 1,416 (64.20)
 587 (26.60)
 1,619 (73.40)
 1,074 (48.70)
 1,132 (51.30)
 1,447 (66.50)
 730 (33.50)
 58 (17–88)
 2,096 (26.80)
 3,675 (47.00)
 2,040 (26.10)
-
-
 1,359 (18.10)
 3,593 (47.90)
 2,544 (33.90)
 6,730 (89.30)
 15 (0.20)
 788 (10.50)
 5,516 (73.10)
 2,025 (26.90)
 5,536 (70.90)
 2,275 (29.10)
 4,731 (60.60)
 3,080 (39.40)
-
-
-
-
 57 (22–90)
 398 (20.97)
 835 (43.99)
 665 (35.04)
 1,342 (72.00)
 521 (28.00)
 361 (19.03)
 835 (44.02)
 701 (36.95)
 1,508 (79.70)
 290 (15.30)
 94 (5.00)
 1,002 (82.10)
 218 (17.90)
 1,337 (70.40)
 561 (29.60)
 351 (18.50)
 1,547 (81.50)
-
-
-
-
Values are presented as median (range) or number (%).
YCC, Yonsei Cancer Center; BCCA, British Columbia Cancer Agency.
a)Missing data were excluded.
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Statistical analysis was performed using SPSS software version 
23.0 (IBM, Armonk, NY, USA), SAS version 9.4 (SAS Institute, 
Cary, NC, USA), and R package version 3.1.3.
Results
1. Patients and tumor characteristics
Patients and tumor characteristics are presented in Table 1. The 
median age of the patients was 49 years (interquartile range, 
43 to 56 years). Compared with the BCCA cohort involved in 
creating the IBTR! 2.0 nomogram, patients had less positive 
resection margin (10.5% vs. 2.5%), less LVI (26.9% vs. 5.60%) 
in our study cohort, respectively. More patients received 
chemotherapy (29.1% vs. 64.2%) and hormone therapy (39.4% 
vs. 73.4%), respectively. We also compared patients and tumor 
characteristics with patients at the University Hospital Leuven. 
Concordant with the BCCA cohort, less positive resection 
margins (5.0% vs. 2.5%) and less LVI (17.9% vs. 5.6%) were 
observed. In addition, more chemotherapy (29.6% vs. 64.2%) 
was performed in our study cohort when compared with the 
University Hospital Leuven cohort (Table 1). 
2. Recurrence
Table 2 provides the results concerning recurrence. The median 
follow-up period was 6.09 years (range, 6 to 23.2 years). 
Among 2,206 patients, 116 patients experienced recurrence. 
Distant metastasis was a dominant pattern of failure in 
patients who received BCS and RT. IBTR was occurred in 16 
patients. We defined the IBTR as local recurrence without 
regional or distant metastasis. Among the local recurrence 
group, there were 3 true recurrences and 8 that occurred 
elsewhere. Regional failure was observed in 15 patients. 
Approximately half of the patients in regional recurrence 
group experienced supraclavicular node recurrence. Among the 
patients who experienced distant metastasis, 15% of patients 
underwent simultaneous locoregional recurrence. The 10-year 
OS, DFS, and cancer specific survival rates were 94.6%, 93.7%, 
and 96.9%, respectively, as shown in Fig. 1. 
3. Factors related to IBTR, OS, and DFS
We conducted a Cox univariate analysis to evaluate the factors 
affecting IBTR, OS, and DFS. Due to the limited number of 
IBTR events in our study, hormone therapy was the only factor 
affecting IBTR (hazard ratio [HR] = 0.22; 95% confidence 
interval [CI], 0.08–0.61; p = 0.004) (Table 3). 
For the univariate analysis, tumor stage (T stage), node 
stage (N stage), tumor grade, LVI were independent prognostic 
factors for OS (Supplementary Table S1). Based on factors 
identified as significant by the univariate analysis, we 
performed the multivariate analysis, which showed that node 
positive status (HR = 1.69, 95% CI, 1.03–2.75; p = 0.037) 
was a prognostic factor of OS. Grade 3 tumors were a poor 
prognostic factor compared with grade 1 tumors (HR = 2.61; 
95% CI, 1.26–5.40; p = 0.01) (Supplementary Table S2).
Addit ional  analys is  was performed to assess  the 
independent prognostic factors for DFS. The T stage, N stage, 
and the tumor grade were significant factors affecting DFS 
Table 2. Patterns of treatment failure after breast conserving 
therapy (n = 116)
Recurrence No. of patients
Locoregional recurrence
   Local recurrence
      Near primary site
      Elsewhere
      Skin
   Regional recurrence
      SCL
      IMN
      AXL
      SCL + IMN
Distant metastasis
Locoregional + distant metastasis
31
16
5
8
3
15
7
1
6
1
72
13
SCL, supraclavicular lymph node; IMN, internal mammary; AXL, 
axillary lymph node.
Fig. 1. Kaplan-Meier plot of overall survival (OS), cancer-specific 
survival (CSS), and disease-free survival (DFS).
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on univariate analysis (Supplementary Table S1). For the 
multivariate analysis, the N stage (HR = 1.70; 95% CI, 1.18–
2.24; p = 0.004) was the only independent prognostic factor 
for DFS (Supplementary Table S2).
4. Validation 
To validate the web-based IBTR! 2.0 nomogram, we assess the 
data with respect to discrimination and calibration. To evaluate 
discriminative ability of this nomogram, we conducted 
c-statistics. The area under ROC curve was 0.607 in this 
nomogram indicating it has poor discrimination. 
Calibration plots of the IBTR! 2.0 nomogram is shown in 
Fig. 2. Each figure represents the relationship between the 
nomogram estimated IBTR rate and the observed IBTR rate. 
The 45° line represents the ideal nomogram, demonstrating 
that the nomogram predicted outcome would be concordant 
with the observed outcome. The error bar in calibration 
plot represents the IBTR! 2.0 nomogram performance when 
Fig. 2. Calibration plot for IBTR! 2.0 nomogram. The nomogram 
predicted recurrence rate was plotted against the observed 
recurrence rate. 
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Table 3. Prognostic factors affecting ipsilateral breast tumor recurrence rate
Variable
Univariate analysis
No. of event (n = 16) HR (95% CI) p-value
Age (yr)
pT stage
    T3–4 
    T1–2
pN stage 
    N+
    N0
Location
    Inner 
    Outer and central
Tumor grade
    3
    2
    1
Resection margin
    Negative
    Close (≤2 mm)
    Positive
Lymphovascular invasion 
    Positive
    Negative
Chemotherapy 
    Yes 
    No
Hormone therapy 
    Yes 
    No
 
 10 / 532
 6 / 1,670
 1 / 445
 15 / 1,753
 5 / 730
 11  / 1,447
 6  / 520
 6  / 936
 3  / 564
 15  / 2,135
 0  / 12
 1  / 56
 1  / 123
 15  / 2,082
 10  / 1,416
 6  / 790
 6  / 1,619
 10  / 587
 1.00 (0.95–1.05)
 1.82  (0.66–5.02)
 0.23  (0.31–1.76)
 0.86  (0.29–2.48)
 1.57  (0.77–3.20)
 1.56  (0.56–4.37)
 1.20  (0.16–9.11)
 0.87  (0.31–2.41)
 0.22  (0.08–0.61)
0.906
0.246
0.159
0.781
0.208
0.395
0.858
0.796
0.004
HR, hazard ratio; CI, confidence interval.
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applying data from our study database. A Kaplan-Meier 
analysis for IBTR rate was done based on four risk group. The 
graph for Kaplan-Meier analysis is shown in Fig. 3. Four groups 
were classified according to predicted 10-year IBTR risk by the 
IBTR! 2.0 nomogram. Large discrepancies between nomogram 
IBTR predictions and observed IBTR rates were observed in 
overall risk groups. The expected and observed IBTR rate was 
2.1% and 0.6% in group 1, 3.8% and 0.9% in group 2, 6.5% 
and 1% in group 3, and 11.2% and 0% in group 4, respectively. 
Discussion and Conclusion
The IBTR! 2.0 nomogram is a predictive tool for local 
recurrence after breast conserving therapy. There are several 
researchers validating the IBTR! 2.0 nomogram using their own 
database [6,11,12]. Nevertheless, the clinical utility of IBTR! 2.0 
nomogram should continue to be tested under heterogeneous 
patient population conditions and clinical settings [13]. 
Considering discordant findings from mentioned validation 
studies, we believe our findings validating the IBTR! 2.0 
nomogram with our own dataset add meaningful knowledge 
to the existing literature
In the current study, the IBTR! 2.0 nomogram showed poor 
discriminative abilities with a C-statics value of 0.607. This 
value is consistent with study from University Hospital Leuven 
that had C-static values between 0.57 and 0.59 [11]. However, 
this result was slightly lower compared with a study from 
BCCA and Samsung Medical Center (C-statics = 0.66 and 0.67 
respectively). In studies from BCCA and the Samsung Medical 
Center, approximately 5% of patients experienced IBTR [6,12]. 
However, Leuven study presented 1.8% of IBTR rate showing 
much less recurrence rate [11]. Our study showed only 0.7% 
of local recurrence, demonstrating a huge discrepancy with 
the original article and the Samsung Medical Center study. 
Taken together, IBTR! 2.0 nomogram seems to have modest 
discriminative ability for predicting the IBTR risk rate. With 
respect to modest discriminative abilities in our study, an 
extremely low rate of events would be main reason. 
In cohort studies from Massachusetts General Hospital and 
the BCCA which created the IBTR! 2.0 nomogram, low and 
moderate risk patients seemed to accurately predict the IBTR 
risk rate by the IBTR! 2.0 nomogram. However, in patients with 
high risk features, the IBTR! 2.0 nomogram overestimated the 
risk [6]. In the current study, the calibration results showed 
that IBTR! 2.0 nomogram overestimated the IBTR risk in overall 
risk groups. Consistent with our results, the University Hospital 
Leuven results indicated overestimation of IBTR risk in all risk 
groups [11]. Contrary to BCCA and our study, Samsung Medical 
Center data demonstrated an underestimation in the higher 
risk group. However, low and moderate risk groups showed 
high correlation between actual and estimated IBTR risk [12]. 
This implies that the calibration results of IBTR! 2.0 nomogram 
could be varied across the institutions. 
The reason for disparity in calibration might originate from 
several factors. There are some differences in patient and 
tumor characteristics when compared to other study groups. 
Our results showed a much lower IBTR rate than other studies. 
Our study cohort had fewer high grade histology tumors, more 
use of chemotherapy and more use of hormonal treatment 
compared with the BCCA cohort. Other differences also existed 
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Fig. 3. Kaplan-Meier plot for observed 
ipsilateral breast tumor recurrence (IBTR) 
in four risk groups, based on predicted 
recurrence less than 3%, 3%–5%, 5%–10%, 
and higher than 10%. 
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such as resection margins (positive margin, 2.50% vs. 10.50%), 
LVI (5.60% vs. 26.90%) and tumor grade (grade 3, 25.70% 
vs. 33.90%). The LVI rates seem to be much lower in our 
institution. This may be partly explained by LVI detection which 
is somewhat subjective  [14]. 
Wide margin resection performed in our institution is done 
to obtain additional tissue from the circumferential margin 
of the cavity after lumpectomy. Randomized, controlled trial 
conducted at the Yale cancer center proved that wide margin 
resection tended to reduce the odds of positive margins 
(OR = 2.06; 95% CI, 0.98–4.32; p = 0.06) [7]. Considering 
that resection margin status has been closely associated 
local recurrence of breast cancer, wider resection margin 
in our institution might attribute to the overall low rate of 
IBTR  [15-17]. Another possible reason is the use of modern 
chemotherapy. With respect to chemotherapy, there was 
high discrepancy in the HR of chemotherapy use between 
our cohort and the model cohort. The HR of chemotherapy 
in our cohort was 0.37 in the multivariate Cox-analysis (data 
not shown), which seems to be much lower than the original 
report [6]. Additional paclitaxel for adjuvant chemotherapy 
offered better local control than adjuvant doxorubicin/
cyclophosphamide with comparable toxicity [18]. In the 
trastuzumab era, trastuzumab is effective for reducing 
locoregional recurrence with human epidermal growth factor 
receptor 2 positive tumors [19]. Also, patients who received 
hormone therapy had less locoregional recurrence than 
patients without hormone therapy [20,21]. Taken all together, 
development of systemic therapy such as, chemotherapy, 
hormone therapy and trastuzumab might contribute to 
lowering the rate of IBTR, which led to an underestimation. 
There are several limitations inherent to the retrospective 
nature of this study, even though our study registry has been 
prospectively collected data. As our cohort data was collected 
for a long period, from 1999 to 2012, there were several 
changes over time, such as criteria for positivity of hormone 
receptor or LVI, and changes in systemic treatments overtime. 
Secondarily, a small number of recurrence event limits the 
complete statistical analysis. Finally, our median follow-up 
time was 73 months, relatively short follow-up period in breast 
cancer. These factors could underestimate the IBTR risk.
In conclusion, this study showed that the IBTR! 2.0 
nomogram seems to have a poor discriminative ability with a 
tendency to over-estimate risk rate. Wide resection margins 
and use of modern chemotherapy in our cohort might 
attribute to an overall low IBTR rate, which might be the main 
reason for the underperformance of the IBTR! 2.0 nomogram. 
Caution is needed to interpret the predicted value before 
validating the nomogram by their own dataset. 
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